drugset / Trial / NCT02898779

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1

NCT02898779

Phase 1 Completed 36 enrolled University of Mississippi, Oxford
RandomizedCrossoverSingle-blindBasic science

Summary

To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers. The specific aim is the comparative evaluation of the metabolism, pharmacokinetic behavior, and tolerability of the isomers of PQ (RPQ and SPQ and the racemic mixture RSPQ) in normal healthy human volunteers.

Timeline

Start
2017-05-01
Primary completion
2018-03-01
Completion
2018-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Primaquine Small molecule Oral
Subject R-Primaquine Unknown 15 mg Oral
Subject R-Primaquine Unknown 22.5 mg Oral
Subject S-Primaquine Unknown 15 mg Oral
Subject S-Primaquine Unknown 22.5 mg Oral
Subject SR Primaquine Unknown 30 mg Oral
Subject SR Primaquine Unknown 45 mg Oral

Indications